Search 

a large hospital

CICCB is an investment company, cofounded by China International Capital Corporation Limited (‘CICC’) and CCB Trust Co., Ltd. CICC is the No.1 investment bank in China which was founded in 1995 as a joint venture of China Construction Bank and Morgan Stanley. And CCB trust is the No.1 trust in China, with AUM more than 250 bn USD. In addition, CCB trust is the wholly owned subsidiary of China Construction Bank, one of Top 4 state owned banks in China. Our main business covers asset management, IPO, M&A and strategic investment for industry. Leveraged by shareholders' strong resource, CICCB's investment areas cover full value chain, including VC, PE, pre-IPO and other stages. Target industries include healthcare, TMT, consumer-related and other emerging strategic industries. As a strategic integration platform for CICC and CCB, CICCB is committed to becoming an all-round asset management institution with global influence in key areas.

中信资本

Advanced investment bank of China

Medical platform who has got a medical application named Congo medika (available on Google playstore) that offer 3 services :medical home care, home delivery of drug and useful health advices

Connexin Therapeutics Ltd. is a UK-based biopharmaceutical company specializing in the Discovery and development,, of drugs targeting connexins, initially for the prevention of vision loss and blindness associated with the eye disease known as glaucoma. While there are a variety of glaucoma subtypes, a common hallmark is the progressive loss of vision due to the gradual cell death in the retina and optic nerve triggered by elevated intraocular pressure. Many drugs are available to reduce intraocular pressure, yet none have been shown to directly protect cells in the retina or optic nerve, and hence prevent them from dying. Thus, vision loss inevitably occurs, even in well-treated patients, and severe vision impairment remains common in these patients.
Connexin Therapeutics raised ~£150,000 in Seed financing in early 2019. These funds are being used to synthesize and test novel small molecules in animal models of glaucoma. Selected results from these studies are presented in this document. These compounds are based on a molecule which has already demonstrated efficacy in mouse models of glaucoma. Thus, these data supplement and extend the work already published.
We are currently raising ~£2,000,000 to expand our synthesis and optimize our lead compounds. After ~8-10 quarters of work we anticipate having a library of patentable compounds which are highly selective for our target, backed by cell and animal data. We may also have a second compound which inhibits a different retinal target for a different set of conditions. Future financing rounds will take one or both leads into formulation development, safety studies, and clinical trials, while also fueling our expansion into other indications with this same mechanism of action.

Convalife is an innovative, research-based, clinical stage biopharmaceutical company focused on bringing innovative therapies to patients with cancer, autoimmune and infectious diseases in China and around the world.

Big pharm in China